Avadel Pharmaceuticals to Present at Upcoming December 2020 Investor Conferences
Avadel Pharmaceuticals (Nasdaq: AVDL) announced participation in two major upcoming conferences focused on healthcare.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Avadel Pharmaceuticals (Nasdaq: AVDL) announced participation in two major upcoming conferences focused on healthcare. The 32nd Annual Piper Sandler Virtual Healthcare Conference is scheduled for December 1-3, 2020, where Avadel's management will present. Additionally, they will present at the 3rd Annual Evercore ISI HealthCONx Conference on December 3, 2020, at 9:15 a.m. ET. Webcasts for both events will be available on Avadel's website and through the conference sites.
The company's primary focus remains on developing FT218, a once-nightly formulation of sodium oxybate aimed at treating narcolepsy.
Details
News Market Reaction – AVDL
The recorded move for AVDL in the trading session of this news was +2.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, Ireland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that members of the Avadel management team will present at both the 32nd Annual Piper Sandler Virtual Healthcare Conference and the 3rd Annual Evercore ISI HealthCONx Conference that are being held in December 2020.
| Event: | 32nd Annual Piper Sandler Virtual Healthcare Conference |
| Date: | December 1st - 3rd |
| Webcast: | A webcast presentation will be available via the Piper Sandler conference site (click here) from November 23rd to December 3rd. In addition, the webcast will be posted on Avadel’s website, www.avadel.com, for 90 days from being made available. |
| Event: | 3rd Annual Evercore ISI HealthCONx Conference |
| Date: | Thursday, December 3rd |
| Time: | 9:15 a.m. ET |
| Webcast: | A webcast will be available at (click here), as well as on the “Investors” section of the Company’s website at www.avadel.com. A replay of the webcast will be available on Avadel’s website for 90 days following the presentation. |
About Avadel Pharmaceuticals plc:
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Company’s primary focus is the development and FDA approval of FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy. For more information, please visit www.avadel.com.
Contacts:
| Tom McHugh | |
| Chief Financial Officer | |
| Phone: (636) 449-1843 | |
| Email: tmchugh@avadel.com | |
| Tim McCarthy | |
| LifeSci Advisors, LLC | |
| Phone: (212) 915-2564 | |
| Email: tim@lifesciadvisors.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.